Compound details
Butyl 3-O-caffeoylquinate
| Compound ID | CDAMM01235 |
|---|---|
| Common name | Butyl 3-O-caffeoylquinate | IUPAC name | butyl 3-[3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]-1,4,5-trihydroxycyclohexane-1-carboxylate |
| Molecular formula | C20H26O9 |
| Retention time | 12.14 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 411.166 | Theoretical mz | 411.165 |
| Error | 1.03 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 6.805 |
| Inchi key | VNLREARKISTOAD-ALCCZGGFNA-N |
|---|---|
| Smiles | O=C(OC1CC(O)(C(=O)OCCCC)CC(O)C1O)C=CC2=CC=C(O)C(O)=C2 |
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P02766 | TTR | Transthyretin | T86462 | SEA |
| P05067 | APP | Beta amyloid A4 protein | T87024 | SEA |
| P43166 | CA7 | Carbonic anhydrase VII | T37541 | SEA |
| P23280 | CA6 | Carbonic anhydrase VI | T06569 | SEA |
| Q9ULX7 | CA14 | Carbonic anhydrase XIV | T31992 | SEA |
| P11388 | TOP2A | DNA topoisomerase II alpha | T17048 | SEA |
| P10636 | MAPT | Microtubule-associated protein tau | T45593 | SEA |
| Q04760 | GLO1 | Glyoxalase I | T88285 | SEA |
| Q16236 | NFE2L2 | Nuclear factor erythroid 2-related factor 2 | T88505 | SEA |
| O43826 | SLC37A4 | Glucose-6-phosphate translocase | T47306 | SEA |
| Q15466 | NR0B2 | Nuclear receptor subfamily 0 group B member 2 | T89859 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T86462 | DI0026 | Amyloidosis | [ICD-11: 5D00] | P02766 | TTR |
| T87024 | DI0025 | Alzheimer disease | [ICD-11: 8A20] | P05067 | APP |
| T87024 | DI0122 | Diagnostic imaging | [ICD-11: N.A.] | P05067 | APP |
| T06569 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | P23280 | CA6 |
| T06569 | DI0372 | Seborrhoeic dermatitis | [ICD-11: EA81] | P23280 | CA6 |
| T31992 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | Q9ULX7 | CA14 |
| T31992 | DI0204 | Inborn metabolism deficiency | [ICD-11: 5C50-5C59] | Q9ULX7 | CA14 |
| T17048 | DI0012 | Acute myeloid leukaemia | [ICD-11: 2A60] | P11388 | TOP2A |
| T17048 | DI0225 | Kaposi sarcoma | [ICD-11: 2B57] | P11388 | TOP2A |
| T17048 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | P11388 | TOP2A |
| T45593 | DI0012 | Acute myeloid leukaemia | [ICD-11: 2A60] | P10636 | MAPT |
| T45593 | DI0025 | Alzheimer disease | [ICD-11: 8A20] | P10636 | MAPT |
| T45593 | DI0265 | Mild neurocognitive disorder | [ICD-11: 6D71] | P10636 | MAPT |
| T88285 | DI0210 | Influenza | [ICD-11: 1E30-1E32] | Q04760 | GLO1 |
| T88505 | DI0038 | Ataxic disorder | [ICD-11: 8A03] | Q16236 | NFE2L2 |